Creating a Third Revenue Stream Through Joint Development of Biopharmaceutical CMC and Biosimilars

An initiative to establish new revenue streams through the joint development of biopharmaceutical CMC and biosimilar drugs with KWB and other partners, as well as through licensing and transfers, contracted development support, and profit sharing.